Detailed price information for Keros Therapeutics Inc (KROS-Q) from The Globe and Mail including charting and trades.

Last of two parts THE real damage in Davos last week was not Donald Trump’s public humiliation (TMT, Jan. 28, 2026). It was ...

Summit Therapeutics nears a 2026 FDA decision for ivonescimab with $710M cash and Akesobio catalysts. Find out why SMMT stock is upgraded to hold.

Global Mice Model Market OverviewThe global mice model market is projected to grow at an approximate rate of 9% over the next five years, supported by increasing demand for personalized medicine, ...

We're getting better networking and cleaner code in this stable release.

Daiichi Sankyo & AstraZeneca’s Enhertu approved in China as first and only HER2 directed ADC for second-line treatment of patients with HER2 positive metastatic gastric cancer ...

Leaders with CureDuchenne say approvals are expected this year for several new treatments for Duchenne MD, making it "an ...

Three years after Elevidys treatment, boys with DMD show sustained motor function compared with expected disease progression.

Metabolic dysfunction-associated steatotic liver disease (MASLD) has become the leading cause of liver disease worldwide, affecting one in three people.1,2 The inflammatory form of MASLD, namely ...

Everything you need to know about all the Grow A Garden Mutations, as well as which ones are the most valuable and how pets can affect crops. Mutations are the key to making your fortune in Grow A ...